Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Monday

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. On average, analysts expect Fulcrum Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ:FULC traded down $0.30 on Wednesday, hitting $5.05. 1,026,730 shares of the company's stock were exchanged, compared to its average volume of 968,802. The stock has a market capitalization of $272.81 million, a price-to-earnings ratio of -16.30 and a beta of 2.29. Fulcrum Therapeutics has a 12 month low of $2.32 and a 12 month high of $10.13. The business's 50 day simple moving average is $3.30 and its two-hundred day simple moving average is $3.67.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "neutral" rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $8.63.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.